uniQure stock rating reiterated by TD Cowen after positive Huntington’s data
PositiveFinancial Markets

TD Cowen has reiterated its positive stock rating for uniQure following encouraging data related to Huntington's disease. This is significant as it reflects confidence in uniQure's potential to make strides in treating this challenging condition, which affects many individuals and families. Investors may see this as a promising opportunity in the biotech sector.
— Curated by the World Pulse Now AI Editorial System